U.S. Election Outlook: Presidential & Congressional Scenario Planning for Biopharma Priorities

The fast-approaching November U.S. elections may impact the biopharma industry particularly with potential leadership changes in the executive branch and Congress. A recent poll reports that 68% of Americans are optimistic that a treatment would be developed for COVID-19 suggesting that there is some shift in public perception towards the industry. This panel will examine policy proposals of candidates, assess the risks of policy recommendations that could limit innovation, and consider opportunities for the industry to recommend priorities that provide the greatest value for continued therapeutic development and treating patients.